Skip to content
The Nexus
DossierENTITY

Baricitinib

Coverage of Baricitinib in the Nexus archive.

Earliest in view: Jun 7 · 15:14 UTCMost recent: Jun 7 · 15:14 UTC
Co-mentioned in this coverage
Olumiantproduct1venous thromboembolismtopic1tumor necrosis factor inhibitorstopic1FDAorganization1
Recent coverage
  • HEALTHJun 7 · 15:14 UTCMEDPAGE TODAY
    Post-Marketing Studies Document Extra VTE Risk for Baricitinib

    Baricitinib (Olumiant) failed to demonstrate noninferiority to tumor necrosis factor (TNF) inhibitors for venous thromboembolism (VTE) risk in FDA-required postmarketing studies, according to a researcher. The analysis found an increased VTE risk associated with the drug compared to TNF inhibitors.

Baricitinib · Dossier · The Nexus